BMJ Open (Jul 2021)

Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries

  • Katia M C Verhamme,
  • Henrik T Sørensen,
  • Douglas P Kiel,
  • Ian C K Wong,
  • Sirpa Hartikainen,
  • Anna-Maija Tolppanen,
  • Amy Hai Yan Chan,
  • Jenni Ilomäki,
  • J Simon Bell,
  • Kelvin Bryan Tan,
  • Ganga Ganesan,
  • Tzu-Chieh Lin,
  • Ching-lung Cheung,
  • Cécile Droz-Perroteau,
  • Nobuhiro Ooba,
  • Kiyoshi Kubota,
  • Manju Chandran,
  • Hongxin Zhao,
  • Chor-Wing Sing,
  • Sharon Bartholomew,
  • Corina Bennett,
  • Kebede Beyene,
  • Pauline Bosco‐Lévy,
  • Caroline Y Doyon,
  • Han Eol Jeong,
  • Jeff Lange,
  • E Michael Lewiecki,
  • Jiannong Liu,
  • Mirhelen Mendes de Abreu,
  • Nicolas Moore,
  • James O’Kelly,
  • Alma B Pedersen,
  • Sawaeng Watcharathanakij

DOI
https://doi.org/10.1136/bmjopen-2020-047258
Journal volume & issue
Vol. 11, no. 7

Abstract

Read online

Introduction Hip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records.Methods and analysis This retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported.Ethics and dissemination Each participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences.